YIH
ELDN icon

Y-Intercept (HK)’s Eledon Pharmaceuticals ELDN Stock Holding History

Y-Intercept (HK)’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,065
Closed -$40.9K – 1720
2025
Q1 		$40.9K Buy
+12,065
New +$49.7K ﹤0.01% 1135

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Y-Intercept (HK)'s ELDN Position: Q2 2025 in Review

Y-Intercept (HK) sold out of Eledon Pharmaceuticals (ELDN) in Q2 2025, closing a stake of 12,065 shares — an estimated $40.9K sold.

Y-Intercept (HK) first reported a position in ELDN in Q1 2025 and held it in 1 quarter. The position peaked at $40.9K in Q1 2025. 85 funds tracked by Wall St. Rank hold ELDN as of Q2 2025.

  • Y-Intercept (HK) reported no remaining Eledon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 12,065 Eledon Pharmaceuticals shares in Q2 2025, an estimated $40.9K.
  • Y-Intercept (HK) first reported a position in Eledon Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Eledon Pharmaceuticals position peaked at $40.9K in Q1 2025.
  • 85 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2025.

Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.